Purchase Order 75N93025P01035

Award Date 5/27/25
Potential Completion Date 7/31/25
Potential Value $17K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Bethesda, MD 20892, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This firm fixed price purchase order was awarded by the National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, to Adaptive Biotechnologies Corporation (also doing business as Adaptive) for IMMUNOSEQ MMTCRB SERVICE. The contract, valued at $12,200.00, does not have a set-aside designation. Through this award, Adaptive Biotechnologies will provide specialized sequencing and testing services to support HHS research programs. Adaptive...
This firm fixed-price federal contract award is for the provision of IMMUNOSEQ MMTCRB SEQUENCING SERVICE (DEEP) by Adaptive Biotechnologies Corporation, doing business as Adaptive, to the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases. The $10,400.00 contract has a completion date of July 3, 2024. Adaptive Biotechnologies is an established provider of immune-driven medicine services and products to federal...
This is a $12,300 firm fixed price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services (HHS), to Adaptive Biotechnologies Corporation (Adaptive) for "IMMUNOSEQ MMTCRB SEQUENCING SERVICE". The contract has an ultimate completion date of December 31, 2023 and was awarded on September 19, 2023 without a set-aside designation. Adaptive, a for-profit organization, has previously...
The U.S. National Institute of Allergy and Infectious Diseases (NIAID) awarded a $14,690 firm fixed-price purchase order to Adaptive Biotechnologies Corporation (doing business as Adaptive) for ImmunoSEQ sequencing services. The contract has an ultimate completion date of December 20, 2024. Adaptive is a commercial provider of immune-driven medicine services and products, and has previously received federal contracts and grants from the Department of Health and Human Services (HHS), Department...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), awarded a firm-fixed price sole source contract to Adaptive Biotechnologies Corporation, a small business, for ImmunoSEQ hsTCRB v4 Service (Deep)-Academic RUO and DNA Extraction Service-immunoSEQ, with a ceiling value of $99,427.50. The contract is for specialized testing and genomic sequencing services that support NIAID's research programs. Adaptive Biotechnologies has a...
The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases awarded a firm fixed price purchase order contract to Adaptive Biotechnologies Corporation ("Adaptive") for immunosequencing extraction services. The $12,750 contract was awarded on December 10, 2019 with a completion date of December 10, 2020. Adaptive is a commercial provider of immune-driven medicine services and products. The company has...
This is a firm fixed-price purchase order issued by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services (HHS), to Adaptive Biotechnologies Corporation (doing business as Adaptive) for $6,200. The contract is for repertoire sequencing services, which involve analyzing the adaptive immune system's T-cell and B-cell receptors. This award supports NIAID's research programs. Adaptive, a commercial provider of immune-driven medicine,...
The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases awarded a $14,225.00 firm fixed price purchase order to Adaptive Biotechnologies Corporation, doing business as Adaptive, for immunosequencing extraction services. The contract supports NIH research programs and does not have a set-aside designation. Adaptive has previously provided specialized testing and genomic sequencing services to HHS, the Department...
This is a firm fixed price purchase order valued at $234,900.00 awarded by the National Institutes of Health (NIH) Clinical Center to Adaptive Biotechnologies Corporation, doing business as Adaptive, with a period of performance ending on September 30, 2024. The contract does not have a set-aside designation. Adaptive Biotechnologies is a commercial provider of immune-driven medicine services and products, including immunosequencing, DNA extraction, and COVID-19 research services for the...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $20,197.60 firm-fixed-price purchase order for DNA sequencing services to Adaptive Biotechnologies Corporation, doing business as Adaptive. The contract has no set-aside designation and was completed on June 21, 2019. Adaptive is a commercial provider of immune-driven medicine services and products, and has previously received federal contracts from the...

This federal contract award is for IMMUNOSEQ MMTCRB SERVICE (DEEP), catalog # ISS20001, with a quantity of 16, awarded to Adaptive Biotechnologies Corporation by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the National Institutes of Health (NIH). The contract has a firm fixed price of $16,560.00 and a completion date of July 31, 2025. This is not a set-aside contract. Adaptive Biotechnologies is a for-profit organization that specializes in advanced genomic sequencing technologies, particularly focused on immunosequencing and minimal residual disease testing. The company has a significant Blanket Purchase Agreement (BPA) with the Department of Veterans Affairs' Veterans Integrated Service Network 1, valued at $828,750 through July 2027, to provide ClonoSEQ minimal residual disease testing services to VA medical facilities in the New England region.

Generated 5/28/25, 10:42 AM